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Abstract
Background: Self-administration of recombinant human follicle-stimulating hormone (r-hFSH) can be performed
using injection pen devices by women undergoing assisted reproductive technology procedures. The objective of
this study was to explore the use of the prefilled follitropin alfa pen in routine assisted reproductive technology
procedures in Germany.
Methods: This prospective, observational study was conducted across 43 German IVF centres over a period of 1.75
years. Patients who had used the prefilled follitropin alfa pen in the current or a previous cycle of controlled
ovarian stimulation completed a questionnaire to assess their opinions of the device.
Results: A total of 5328 patients were included in the study. Of these, 2888 reported that they had previous
experience of daily FSH injections. Significantly more patients reported that less training was required to use the
prefilled follitropin alfa pen than a syringe and lyophilized powder (1997/3081 [64.8%]; p < 0.001 ‘less’ versus ‘more’
training). Significantly more patients rated the prefilled follitropin alfa pen as easier in terms of use (2321/3206,
72.4%; p < 0.001 ‘much more easy’ versus ‘less easy’) and daily injection (2384/3262, 73.1%; p < 0.001 ‘much more
easy’ versus ‘less easy’) than existing injection methods. Approximately one third of respondents rated the prefilled
follitropin alfa pen as easier to use than the follitropin beta pen with reloadable cartridges. The majority (3378/
4024, 83.9%) of patients had a general preference for the prefilled follitropin alfa pen over other injection methods.
Conclusions: In this questionnaire-based survey, routine use of the prefilled follitropin alfa pen was well accepted
and associated with favourable patient perceptions. Users of the pen found it easier to initially learn how to use,
and subsequently use, than other injection methods. In general, the prefilled follitropin alfa pen was the preferred
method for self-administration of gonadotrophins. Together with previous findings, the results here indicate a high
level of patient satisfaction among users of the prefilled follitropin alfa pen for daily self-administration of r-hFSH.
Background
Exogenous follicle-stimulating hormone (FSH) is used
for ovulation induction and controlled ovarian stimula-
tion (COS) during fertility treatment. Recombinant
human FSH (r-hFSH) was first introduced into the mar-
ket in 1995 and, unlike previously used sources of gona-
dotrophins, provides an unlimited, consistent, pure
supply of FSH [1]. Two r-hFSH products are now com-
mercially available - follitropin alfa and follitropin beta.
Recent developments in recombinant technology have
led to improvements in the quality and consistency of
gonadotrophins [1,2]. Follitropin alfa (GONAL-f® filled-
by-mass [FbM]) offers the most consistent and precise
dosing of all FSH products [2]. This benefit may result
in shorter fertility treatment regimens, a lower total FSH
dose requirement, and greater consistency in the ovarian
response [3-6].
As r-hFSH can be administered subcutaneously, it is
suitable for self-injection by patients. r-hFSH was origin-
ally supplied in single or multidose vials or ampoules for
reconstitution and injectionu s i n gas y r i n g e ,b u ti sn o w
available in premixed solutions for use with injection-
pen devices. Two injection-pen devices for the
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The GONAL-f® (FbM) Prefilled Pen (the GONAL-f® Pre-
filled Pen is available for use in the USA as the
GONAL-f® Revised Formulation Female [RFF] Pen;
Merck Serono S.A. - Geneva, Switzerland, an affiliate of
Merck KGaA, Darmstadt, Germany) is prefilled with
premixed follitropin alfa, is ready-to-use and disposable,
whereas the Puregon Pen® (the Puregon Pen® is available
for use in Japan and the USA as the Follistim Pen®;
Organon, Roseland, NJ, USA) is a reusable device,
designed for use with premixed, prefilled loadable car-
tridges of follitropin beta.
An observational study was conducted in Germany
over almost 2 years to explore patient perceptions of the
prefilled follitropin alfa pen for the administration of r-
hFSH in routine assisted reproductive technology
(ART). Here, we present the results of a questionnaire-
based survey to assess patients’ evaluation of the pen, its
perceived ease of use, and acceptability versus previously
used injection methods.
Methods
Patients
This was a prospective, observational study conducted
across 43 German IVF centres, from April 2004 until
December 2005. Routine clinical data for patients under-
going cycles of COS for conventional IVF or intracyto-
plasmic sperm injection were entered prospectively into
an electronic database (RecDate). Only one cycle per
patient was included in this study.
Assessment
When patients returned for oocyte retrieval, those who
had used the prefilled follitropin alfa pen were asked to
complete a multiple-choice questionnaire comparing
their experience with that of other injection methods
(reusable follitropin beta pen, or syringes with ampoules
and vials). If the patient had used the follitropin alfa pen
in a previous stimulation cycle (rather than the current
cycle), she was asked to complete the questionnaire with
reference to the particular cycle in which she had used
the follitropin alfa pen. The questionnaire (see addi-
tional file 1) comprised eight questions specifically
designed to evaluate patients’ opinions on use of the
r-hFSH delivery device (both initial and subsequent use)
and their preferred injection method. Clinical outcomes
for the ART cycles were also recorded.
Statistical methods
Participant responses were presented as a percentage
of the number of responders to the question of inter-
est, and not the entire study population. In accordance
with the design and objectives of the study, statistical
evaluation was focused on the description and
summary of the material obtained by means of descrip-
tive statistics (mean, standard deviation [SD], fre-
quency and percentage). No statistical hypotheses were
specified in advance and, due to the nature of the
study, the sample size was not pre-specified. In retro-
spective analyses, exact binomial tests were used to
assess differences in the proportions of patients who
gave particular responses.
Results
Patient and treatment characteristics
A total of 5328 patients attending the participating cen-
tres during the study period had used the prefilled folli-
tropin alfa pen in the current or a previous cycle of
COS, and were, therefore, eligible for inclusion in this
study. The mean (SD) age was 33.8 (4.3) years (n =
5326); the mean (SD) body mass index was 23.4 (4.2)
kg/m
2 (n = 5279). The mean (SD) number of days of
COS per patient was 10.9 (2.7) days, with a mean (SD)
cumulative dose of 2148 (993) international units of
follitropin alfa per patient.
When questioned about previous experience with daily
injections of FSH, 2888 respondents reported that they
did have experience. The most common preparation of
FSH previously used (by 52.9% of those with prior injec-
tion experience) was that of ampoules containing lyo-
philized powder. In total, 24.9% of patients with prior
experience of daily injections with FSH had previously
used the reusable follitropin beta pen.
Initial use of the prefilled follitropin alfa pen
The majority (3967/5242, 75.7%) of respondents
reported that they were trained to use the prefilled folli-
tropin alfa pen by a nurse. The majority (52.4%) of
respondents required between 5 and 9 min to be trained
to use the pen (Table 1); the mean length of time
required was 7 min. Significantly more respondents with
relevant experience reported that less training was
required to use the prefilled follitropin alfa pen com-
pared with a syringe and lyophilized powder for injec-
tion (1997/3081 [64.8%]; p < 0.001 ‘less’ versus ‘more’
training) (Fig. 1).
Table 1 Time required for training in use of the prefilled
follitropin alfa pen
Variable Value/number of
respondents
Proportion of respondents
(%)
< 5 min 734 23.4
5-9 min 1648 52.4
10-19
min
694 22.1
≥20 min 67 2.1
n = 3143.
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Page 2 of 7Routine daily use of the prefilled follitropin alfa pen
Patients who had used the prefilled follitropin alfa pen
(1040 respondents) and follitropin beta pen (50 respon-
dents) reported that they changed the pen/cartridge a
mean value of 2.3 and 2.4 times per treatment cycle,
respectively.
Significantly more respondents rated the overall ease
of use of the prefilled follitropin alfa pen as easier than
existing injection methods (2321/3206 [72.4%]; p <
0.001 ‘much more easy’ versus ‘less easy’) (Fig. 2). Simi-
larly, significantly more respondents rated daily injection
with the prefilled follitropin alfa pen as easier than exist-
ing injection methods (2384/3262 [73.1%]; p < 0.001
‘much more easy’ versus ‘less easy’) (Fig. 2). Approxi-
mately 60% of respondents with experience of the reusa-
ble follitropin beta pen rated both the use of (411/660)
and daily injection with (402/664) the prefilled follitro-
pin alfa pen as easier than existing injection methods.
On a scale of 1-10 (1 = less easy and 10 = much more
easy) 591/1954 (30.2%) respondents gave a score of
10 when asked to evaluate use of the prefilled follitropin
alfa pen compared with the reusable follitropin beta pen.
The majority (3378/4024, 83.9%) of respondents stated
that they generally preferred the prefilled follitropin alfa
pen when questioned about their favoured method for
injection of r-hFSH (Fig. 3).
Clinical outcomes
The mean (SD) number of oocytes retrieved per cycle
was 9.75 (5.83). Over 90% of cycles resulted in embryo
transfer; the clinical pregnancy rate per transfer was
32.21%. Other clinical outcomes are presented in Table 2.
Out of a total of 1549 pregnancies, there were 363
(23.43%) spontaneous miscarriages and 1076 (69.46%)
live births (data were missing for 110 pregnancies). Of
the 1076 births, there were 841 singleton births, 228
twin births, 6 triplet births and 1 quadruplet birth.
There were 94 cases (1.95% of cycles which resulted in
embryo transfer) of grade II ovarian hyperstimulation
syndrome (OHSS), 22 cases (0.46%) of grade III OHSS;
28 cases of OHSS (0.58%) required hospitalization.
Discussion
In this questionnaire-based survey, the routine use of
the prefilled follitropin alfa FbM, ready-to-use injection
pen was well accepted, and associated with favourable
patient perceptions in 5328 ART cycles. Patients
reported that use of the follitropin alfa pen required less
Less
Equal
More
n = 1997
n = 877
n = 207
6.7%
28.5%
64.8%†
N = 3081
†P < 0.001 versus ‘more’ training.
Figure 1 Comparative amount of training required: prefilled follitropin alfa pen vs reconstitution and injection using a syringe.T h e
number and proportion of patients who reported that the prefilled follitropin alfa pen required ‘less’, ‘equal’ or ‘more’ training than
administration (of reconstituted lyophilized powder in single- or multi-dose ampoules/vials) using a syringe. An exact binomial test was used to
assess the null hypothesis that the proportion of patients who considered the pen to require less training than a syringe was equal to the
proportion who considered the pen to require more training. Patients who responded that the pen and syringe required equal training were
omitted from the analysis.
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Equal
Less easy
(A)
n = 2321
n = 671
n = 214
6.7%
20.9%
72.4%†
N = 3206
†P < 0.001 versus ‘less easy’.
Much more easy
Equal
Less easy
(B)
n = 2384
n = 718
4.9%
22.0%
73.1%†
N = 3262
†P < 0.001 versus ‘less easy’.
n = 
160
Figure 2 Ease of use and daily injection: prefilled follitropin alfa pen vs existing injection methods. The number and proportion of
patients who rated (A) overall ease of use of and (B) daily injection with the prefilled follitropin alfa pen as ‘much more easy’, ‘equal’,o r‘less
easy’ than existing injection methods. Exact binomial tests were used to test the null hypotheses that (a) the proportion of patients who rated
the use of prefilled pen as much more easy than existing injections methods was equal to the proportion who rated the use as less easy and
(b) the proportion of patients who rated the daily injection with the prefilled pen as much more easy than existing injections methods was
equal to the proportion who rated the daily injection as less easy. Patients who responded that the pen was equally as easy to use and use
daily for injection compared with existing injection methods were omitted from the analyses.
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follitropin alfa. The prefilled pen was perceived as being
easier to use than existing injection procedures/devices,
including the reusable follitropin beta pen, and there
was a general preference for the follitropin alfa pen.
Injection-pen devices are used to self-administer medi-
cations that require daily injection on a long-term basis.
Most experience of injection-pen devices to date has
been obtained in diabetic patients who self-inject insulin.
Pen devices are the preferred mode of administration for
insulin, as they have made the injection process easier,
less painful and more convenient. This has resulted in
increased patient acceptance of therapy, and has
improved patient compliance with therapy and treatment
outcomes, as demonstrated by improvements in glycae-
mic control [7-10].
Previous studies have highlighted a number of benefits
for the use of pen devices for the administration of
r-hFSH. Compared with the use of syringes and vials/
ampoules, women undergoing fertility therapy find the
Follitropin alfa pen
Follitropin beta pen
Vial/syringe
Ampoule/syringe
n = 3378
n = 363
n = 251
n = 32 6.2%
0.8%
9.0%
83.9%
N = 4024
Figure 3 Preferred injection methods. The number and proportion of patients who generally preferred the prefilled follitropin alfa pen, the
reusable follitropin beta pen or syringes with ampoules or vials of recombinant human follicle-stimulating hormone.
Table 2 Clinical outcomes (N = 5328)
Outcome
Oocyte retrieval, % (n/N) 97.58 (5199/5328)
Mean (SD) number of oocytes retrieved per cycle with oocyte retrieval* 9.75 (5.83)
Mature oocytes
Number per cycle with oocyte retrieval, mean (SD)
† 8.07 (4.97)
Percentage of retrieved oocytes in cycles with oocyte retrieval, mean (SD) 83.28 (19.2)
2PN oocytes
Number per cycle with oocyte retrieval, mean (SD)
‡ 5.2 (3.69)
Percentage of inseminated/injected oocytes, mean (SD)
‡ 66.2 (27.9)
Cycles with embryo transfer, % (n/N) 90.26 (4809/5328)
Number of embryos transferred, % (n/N)
1 10.15 (488/4809)
2 70.56 (3393/4809)
3 19.30 (928/4809)
Clinical pregnancy rate per embryo transfer, % (n/N) 32.21 (1549/4809)
*n = 5199;
†n = 5128;
‡n = 5109.
PN; pronuclear; SD, standard deviation.
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and more convenient, and their use is associated with
greater patient satisfaction [11-14].
Results from comparative studies of the two available
pen devices for injection of r-hFSH indicate a preference
for the prefilled follitropin alfa pen among both patients
and nurses [15,16]. In a small pilot study, patients
undergoing ART procedures at a German centre were
randomized to either the prefilled follitropin alfa pen or
to the reusable follitropin beta pen [15]. A greater pro-
portion of patients in the group using the prefilled folli-
tropin alfa pen found the pen very easy to handle, and
quicker to learn to use and prepare for injection than
those using the reusable follitropin beta pen. Overall,
the desire to continue using the device was substantially
higher among patients who used the prefilled follitropin
alfa pen than those who used the reusable follitropin
beta pen [15].
A study of patients undergoing ART at an Australian
centre compared the prefilled follitropin alfa pen with
previous experience of the reusable follitropin beta pen
[15,16]. Patients who had used both pen devices scored
many attributes of the prefilled follitropin alfa pen more
favourably than those of the reusable follitropin beta
pen, including the device storage, device use and dose
preparation [15]. Patients also reported less confusion
with use of the prefilled follitropin alfa pen [15]. In the
same study, nurses were asked to complete a question-
naire about their experiences with the prefilled follitro-
p i na l f ap e na n dt h e yw e r ea l s ov e r yp o s i t i v ea b o u tt h e
pen [15].
A survey conducted at a centre in the USA provided
questions for patients about their preferred administra-
tion device following nurse-led training in different
injection-administration methods [16]. Of 94 partici-
pants who expressed a preference for a particular device,
the prefilled follitropin alfa pen was the most popular
(chosen by 68.1% of respondents). This was significantly
more than the proportion of participants who chose the
reusable follitropin beta pen as their preferred device
(24.5%; p < 0.0001). In the same study, factors cited as
being important for device selection included simplicity
and reliability of the dosing mechanism, a design to
minimize the chances of dosing errors and ease of use.
The current study is a much larger evaluation of the
use of the prefilled follitropin alfa pen in routine clinical
practice than those previously conducted. During the
1.75-year study period, approximately 35,000 prospective
ART cycles were performed per year in Germany [17].
These data, therefore, represent 8.7% of all cycles con-
ducted in Germany during the study period. As is typi-
cal in trials utilizing participant questionnaires, not all
participants answered every question. Furthermore, par-
ticipants may have been inconsistent in their answers.
Although we acknowledge the limitations of this study,
our results confirm the findings of previous studies,
which together indicate a high level of patient satisfac-
tion with the prefilled follitropin alfa pen for daily self-
administration of r-hFSH. This may reduce the burden
of fertility treatment, help to improve adherence to ther-
apy and reduce drop-out rates [18,19].
It has been suggested that pen devices may also
improve the efficacy of ovarian stimulation regimens,
with better clinical outcomes associated with use of a
pen device to administer r-hFSH compared with a con-
ventional syringe [13,20,21]. However, more definitive
evidence is needed, and a direct link between use of pen
devices and effect on patient adherence to treatment has
yet to be demonstrated. Clinical outcomes in this study
were favourable, with a mean (SD) number of oocytes
retrieved per cycle of 9.75 (5.83) and a clinical preg-
nancy rate per embryo transfer of 32.21%. As this was
not designed to be a comparative study, only historical
comparisons can be made between the outcomes
obtained in this study with use of the prefilled follitropin
alfa pen and those using other administration methods.
Furthermore, such direct comparisons have inherent
problems, as different study designs and study popula-
tions are used, and data are often inconsistently
reported.
In summary, this study represents almost 9% of ART
cycles conducted in Germany over a 1.75-year period.
The results confirm previous findings on the acceptance,
ease of use and preference for the prefilled follitropin
alfa pen among women who self-administer r-hFSH for
ART. The findings from this and previous user surveys
are reflected in an audited report of pharmacy data
obtained (post-study) for the 2004-2009 period which
show that the majority of patients who have utilized fol-
litropin alfa in Germany in the last 6 years have done so
in the form of a prefilled pen[22].
Additional material
Additional file 1: Questionnaire: comparing injection methods.
Questionnaire
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